Want to see PRTA full AI Analyst Report?
PRTA Stock Chart & Stats
$10.90
<$0.01(0.07%)
At close: 4:00 PM EST
$10.90
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$6.58 - $11.80
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$458.09M
Enterprise Value$204.13
Total Cash (Recent Filing)$329.46M
Total Debt (Recent Filing)$7.65M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 10, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding52,353,237
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.40Price Target Upside96.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.05
Revenue Forecast (FY)$83.32M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetConsistently very low debt provides durable financial flexibility for a clinical‑stage biotech. Low leverage reduces near‑term solvency risk and preserves capacity to raise non‑debt capital or fund partnerships, supporting multi‑year development programs despite operating losses.
Partnered Revenue ModelA collaboration/licensing business model delivers non‑dilutive upfronts, R&D reimbursements, milestone payments and royalties. Partner funding and Roche/Genentech ties validate assets and can materially de‑risk financing needs across multi‑year clinical programs.
Governance ContinuityReaffirmed board and auditor support stable governance and oversight, reducing execution risk through long clinical timelines. Strong shareholder backing enables steady strategic execution and oversight of R&D investments over the next several years.
Bears Say
Negative TTM Gross ProfitSustained negative gross profit and widening net losses signal core unprofitability in current operations. Over months, this erodes equity, constrains reinvestment capacity, and forces reliance on external funding, increasing strategic and dilution risk for clinical execution.
Persistent Cash BurnContinuous negative OCF and FCF imply ongoing funding needs and limited internal cash generation. Over a multi‑month horizon this restricts runway, limits strategic optionality for trials and partnerships, and heightens the probability of future equity or partnership dilution.
Revenue Volatility From MilestonesDependence on lumpy partner payments creates unpredictable top‑line timing that complicates budgeting and runway planning. This structural revenue volatility increases finance complexity, can delay programs if milestones slip, and raises recurring liquidity risk.
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $6.58 and its highest was $11.80 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $458.09M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 10, 2026 which is in 15 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 07, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.948.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.39.
How many shares outstanding does Prothena have?
Prothena has 52,353,237 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of $0.6 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went up 1.996%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.40 (96.33% Upside)
$21.40 (96.33% Upside)
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.36%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
PRTA Stock 12 Month Forecast
Average Price Target
$21.40
▲(96.33% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
2.96% Insiders
20.11% Mutual Funds
1.02% Other Institutional Investors
64.72% Public Companies and
Individual Investors